Trial Profile

Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DFP 13318 (Primary)
Indications CNS cancer; Ependymoma; Glioma; Medulloblastoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

05 Feb 2024 According to a Prolynx media release, the first patient was treated in this trial. NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.
01 Feb 2024 Planned initiation date changed from 31 Jan 2024 to 7 Feb 2024.
25 Jan 2024 Planned initiation date changed to 31 Jan 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com